135 results about "Peptide vaccine" patented technology

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened on the basis of GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway, CD8 + T cells are activated, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.

The invention belongs to the technical field of biological medicines, and particularly relates to an anti-fibrosis peptide fragment, a vaccine and a preparation method and application of the peptide fragment vaccine. In order to explore that the peptide fragment is used as a peptide fragment vaccine for fibrotic diseases, the invention provides an anti-fibrosis peptide fragment, a vaccine and a preparation method and application of the peptide fragment vaccine. According to the application disclosed by the invention, main histocompatibility compound restrictive peptide fragments from six protein sources of fibrosis-specific MAF, FNDC3A, TOP2A, TNS3, APBB2 and OLFML2b are taken as targets for treating and preventing fibrosis diseases, and the six peptide fragments are taken as vaccines, so that various fibrosis diseases are remarkably prevented and treated by inhibiting pathological change and collagenous fiber deposition caused by fibrosis, and the application has the advantages that the application range is wide, and the application prospect is wide. Fibrosis of lung, liver, pancreas and the like is included. The peptide fragment and the peptide fragment vaccine provided by the invention provide candidate schemes for future research on preventive and therapeutic vaccine transformation of fibrotic diseases.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention belongs to the technical field of bioactive peptides and antibodies, discloses an antigen epitope peptide of CaSR, a vaccine, an antibody and application, and aims to construct an egg yolk antibody targeting intestinal tract CaSR by using a polypeptide vaccine technology, improve the calcium absorption efficiency of poultry, seek a scheme for efficiently utilizing calcium elements of poultry, and realize calcium saving and emission reduction in production.

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

A method for developing a therapeutic agent such as, for example, a peptide vaccine. A machine learning model is trained using a metric learning algorithm, training peptide sequence data, and training allele presentation data corresponding to the training peptide sequence data. Peptide sequence data identifying a peptide sequence corresponding to a peptide is received. A peptide sequence vector is generated for each peptide sequence using the peptide sequence data via a machine learning model to form a plurality of peptide sequence vectors. An output is generated using the plurality of peptide sequence vectors. The output provides an indication of similarity between peptide sequences of the plurality of peptide sequences. Based on the output, a set of candidate peptides is selected from the plurality of peptides for development of the therapeutic agent such that the set of candidate peptides includes at least two dissimilar candidate peptides.

The invention relates to the technical field of vaccine preparation methods, in particular to a polypeptide vaccine preparation method which comprises the following components in percentage by mass: 20-30% of a polypeptide antigen, 10-50% of a carrier, 1-10% of an adjuvant, 1-3% of a stabilizer and 1-2% of a preservative. The method comprises the following steps: step 1, antigen epitope preparation, step 2, epitope verification, step 3, polypeptide synthesis, step 4, polypeptide loading, step 5, efficiency evaluation, step 6, pretreatment, step 7, purification processing, step 8, ultrafiltration processing, step 9, identification, step 10, mixing processing and the like. A stabilizer and a preservative are added in the preparation process of the polypeptide vaccine, the stability and safety of the vaccine in the storage and use process can be kept, impurities can be efficiently removed through the steps of physical precipitation, HPLC purification, ultrafiltration processing and the like, the quality of the vaccine can be ensured, customized production can be conducted according to different pathogens and epitopes, and the method is suitable for popularization and application. The medicine is suitable for preventing and treating various diseases.

Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 49. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 81 to 143. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137515 to 137675. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137682 to 137830.

The invention discloses a carrier protein with an adjuvant function and application thereof. The carrier protein with the adjuvant function has a sequence as shown in SEQ ID NO. 1. According to the carrier protein with the adjuvant function, a part of sequence is intercepted from the flagellin FliC of Burkholderia cepacia, so that the adjuvant activity of the flagellin is reserved, and the immunogenicity and antigenicity of the flagellin are reduced; when being applied to a fusion protein or a small-molecule drug, the fusion protein or the small-molecule drug can enhance the immunogenicity, so that the fusion protein or the small-molecule drug has important significance on subunit vaccines, polypeptide vaccines or small-molecule drug carriers.

The invention relates to a nano polypeptide vaccine for preventing colorectal cancer and a preparation method thereof, the vaccine comprises an antigen, and the antigen contains a first polypeptide fragment and a second polypeptide fragment; the amino acid sequence of the first polypeptide fragment is VVGAVGVGK; and the amino acid sequence of the second polypeptide fragment is TPQDSRQVL. The invention provides a novel vaccine entrapped with the colorectal cancer specific antigen peptide, provides a new thought for preventing colorectal cancer, and has a wide prospect. The new antigen polypeptide is selected as a tumor antigen, and the peptide vaccine has the advantages that the peptide vaccine can target multiple tumor-related antigens, the sequence is clear, the good modification potential is achieved, operability is high, preparation and quality control are easy, and the economic cost is relatively low. The vaccine disclosed by the invention is good in safety, has an obvious prevention effect on colorectum, and can be used for obviously prolonging the life cycle of mice, inhibiting tumor growth, improving the anti-tumor immune response of colorectal cancer and inhibiting tumor cell proliferation.

The application discloses a kind of elastin-like polypeptide V 20 K 40 L, mRNA vaccine and preparation method and application in preparation tumor prevention, mitigation or treating drug.The elastin-like polypeptide carrier V 20 K 40 L provided by the application has good biocompatibility, and has no adverse reaction in vivo.The elastin-like polypeptide V 20 K 40 L provided by the application has amphiphilic structure, can be loaded Melan-A mRNA by hydrophobic self-assembly and electrostatic adsorption, and is in the state of shrinkage when higher than Tt temperature, which can prevent the uncontrollable leakage of mRNA.Furthermore, V 20 K 40 L contains lysosome escape peptide, which can further improve the transfection efficiency of mRNA by promoting lysosome escape.The elastin-like polypeptide V 20 K 40 L in the application can deliver Melan-A mRNA efficiently and safely, and realize the prevention and treatment of melanoma.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

A newly developed generalizable screening method enables efficient identification of epitopes, in the proteomes of pathogenic agent is provided. Also disclosed are systems that enable the method as well as epitopes discovered using the method.

The application provides a polypeptide vaccine delivery carrier, which is a phenylalanine-based polyester amide polymer prepared from triethylamine, p-nitrophenol, L-phenylalanine and butanediol. + The polypeptide vaccine has good stability, high antigen presentation effect, and can induce the body to produce effective antitumor CD8 T cell immune response, inhibit tumor growth and metastasis, and improve the effect of immunotherapy.

A system for binding peptide search for immunotherapy is presented. The system includes employing a deep neural network to predict a peptide presentation given Major Histocompatibility Complex allele sequences and peptide sequences, training a Variational Autoencoder (VAE) to reconstruct peptides by converting the peptide sequences into continuous embedding vectors, running a Monte Carlo Tree Search to generate a first set of positive peptide vaccine candidates, running a Bayesian Optimization search with the trained VAE and a Backpropagation search with the trained VAE to generate a second set of positive peptide vaccine candidates, using a sampling from a Position Weight Matrix (sPWM) to generate a third set of positive peptide vaccine candidates, screening and merging the first, second, and third sets of positive peptide vaccine candidates, and outputting qualified peptides for immunotherapy from the screened and merged sets of positive peptide vaccine candidates to support downstream clinical decision making.

Compositions related to synthetic PD-L1 peptides, chimeric PD-L1 peptides, and anti-PD-L1 antibodies, and methods for treating cancer, autoimmune diseases and Alzheimer's disease using said peptides or antibodies are disclosed.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The present invention provides a virus polypeptide-protein subunit combination vaccine based on DNA nanotechnology, and a preparation method and application thereof, belonging to the technical field of biological products. A virus polypeptide-protein subunit combination vaccine based on DNA nanotechnology uses a tetrahedral framework nucleic acid formed by DNA chain assembly as a carrier, a protein antigen that causes virus-specific T cell activation is coupled to one edge of the tetrahedral framework nucleic acid, and a virus B cell epitope peptide is coupled to the four vertices of the tetrahedral framework nucleic acid. Among all virus subunit-peptide vaccines with framework nucleic acids, coupling SARS-Cvo-2N protein to the tetrahedral framework can induce CD4 in a variety of animal models. + T cell activation can induce higher antibody titers and an increase in the ratio of memory B cells to T cells, and can also induce stronger CD8 + T cell activation provides a new idea for constructing efficient viral peptide vaccines based on protein carriers.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The invention discloses a single-target amino acid sequence optimization system based on comprehensive scoring and bit-by-bit iterative optimization. The system comprises the following modules: a mutation probability evaluation module, a target affinity scoring module and a comprehensive scoring module. The comprehensive scoring module and the bit-by-bit iterative optimization strategy of the system significantly improve the optimization efficiency, can quickly screen out high-quality sequences with high affinity and functional rationality in a complex sequence space, reduces the calculation complexity, and ensures that the screening result has scientific rationality and application value. The technology can accelerate optimization design of antibody drugs, target screening of polypeptide vaccines and functional improvement of protein engineering, and provides a reliable tool for drug research and development, precision medicine, personalized treatment and industrial biotechnology.

The application discloses an African swine fever H240R epitope peptide, a monoclonal antibody and application thereof, and relates to the technical field of molecular immunology. The amino acid sequence of the African swine fever H240R epitope peptide is shown as SEQ ID NO. 19 or SEQ ID NO. 20. The monoclonal antibody is monoclonal antibody 11C1A6 or monoclonal antibody 38A3B2; the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 11C1A6 are shown as SEQ ID NO. 9-10, respectively; the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 38A3B2 are shown as SEQ ID NO. 11-12, respectively. The African swine fever H240R epitope peptide is identified, and the monoclonal antibody which is specifically combined with the African swine fever H240R protein is prepared, thereby laying a foundation for preparing an African swine fever polypeptide vaccine and a detection kit.

The invention discloses a preparation method and application of an anti-aging vaccine, and relates to the technical field of medical treatment. Comprising the following steps: 1, synthesizing a polypeptide with a specific sequence; 2, coupling the polypeptide with a carrier protein; adding an immunologic adjuvant, and fully and uniformly mixing at room temperature to obtain a polypeptide solution; 3, freeze-drying the polypeptide solution to obtain a freeze-dried pure product; and dissolving the freeze-dried pure product in ultrapure water, filling into a sterile EP tube, and storing at-20 DEG C to obtain the anti-aging polypeptide vaccine. The anti-aging polypeptide vaccine has the beneficial effects that the polypeptide sequences (A: RRGDGRWKD, B: RSQHLRFPDR, and C: TGRRLFCYS) are designed to create the polypeptide vaccine, and the polypeptide vaccine can effectively act on cells with high expression of GPNMB, so that the anti-aging effect is achieved.

To provide a high immunogenicity anti Aβ vaccine while maintaining an excellent safety profile.SOLUTION: A liposome vaccine composition includes a peptide antigen derived from β-amyloid (Aβ) presented on a surface of a liposome. The vaccine composition further includes a peptide including a universal T-cell epitope encapsulated into the liposome. The vaccine composition also may form a part of the liposome, and includes an adjuvant that may be at least partially presented on the surface of the liposome. The vaccine compositions are used for treating or preventing a disease or a condition related to amyloid beta, or symptoms characterized in loss of cognitive memory ability of a subject or a condition related thereto, inducing protective immune response to the symptom, or alleviating the symptoms. The vaccine composition may be provided as a kit. A related method for producing a liposome vaccine composition is also provided.SELECTED DRAWING: None

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

The invention relates to the technical field of biological medicines, and provides an EGFR L858R mutation specific long peptide vaccine and application thereof. The long peptide vaccine provided by the invention comprises dendritic cells which are loaded by a long peptide antigen modified by a cell penetrating peptide and are induced to be mature. According to the invention, a long peptide sequence with good immunogenicity and affinity is screened out, and specific T cell immune response can be effectively induced. And the long peptide antigen is modified by adopting cell penetrating peptide (CPPs), so that efficient loading and delivery of the long peptide antigen in dendritic cells (DC) are realized. According to the vaccine, the presentation capacity of antigens is remarkably enhanced, CD8 + T cells can be effectively activated, the expression level of IFN-gamma is remarkably improved, and strong specific immune response is induced. In addition, when the vaccine is used in combination with a PD-1 antibody, the tumor immune microenvironment is further improved, and the immune activation effect is enhanced.

This invention relates to the field of biotechnology, and more particularly to a CAR-transduced enhanced H3K27M mutant neoantigen combination peptide vaccine (DCT) and its application. This invention redesigns the H3K27M mutant HLA-A0201 neoantigen peptide and combination, obtaining a polypeptide combination sequence with significantly enhanced affinity for H3K27M+ HLA-A0201 and HLA-B1501 glioma patients. Then, the polypeptides are used to load dendritic cells (DCs) in vitro, DCs are mixed with T cells to obtain DCT cells, and DCT cells are infected with CAR or CAR-like lentiviruses to obtain DCART. Experiments show that, compared with DCT or CAR-T cells, the DCART cells have a better tumor-killing effect on H3K27M mutant tumors. + DIPG and DMG bring new treatment technologies.